| ERA4HEALTH - European partnership fostering a European Research Area (ERA) for health research |
| Duration: |
1. 11. 2022 - 30. 10. 2029 |
| Evidence number: |
101095426 |
| Program: |
Horizont Európa |
| Project leader: |
doc. MUDr. Imrich Richard, DrSc. |
| SAS cosolvers: |
Mgr. Havranová Andrea, doc. MUDr. Penesová Adela, PhD., doc. MUDr. Rádiková Žofia, PhD., MUDr. Vlček Miroslav, PhD. |
| Annotation: |
Excellent EU programs push health R&I but are not sufficient. Synergy with strategic initiatives in MS and a new model for impactful collaborations are needed to address the challenges for health. ERA4Health brings the opportunity to increase EU transnational collaborative research funding by creating a funding body for joint programming in priority areas addressing EU Public Health Needs, with total duration of 7 years. ERA4Health focuses on tackling diseases and reducing disease burden and the following challenges: 1) the increasing demand for a better quality of life and a better care of patients, 2) the need to transform public health care systems in more effective, efficient, equitable, accessible, and resilient ones and 3) the need to strengthen disease prevention and health promotion. In this view, ERA4Health objectives are: .SO1- Support relevant medical research including clinical fields and intervention areas (prevention, diagnosis, treatment) .SO2- Improve the utilisation of existing health technologies in clinical practice .SO3- Build capacity, in particular in conducting Investigator Initiated Clinical Studies at EU scale .SO4- Implement and advance the practice of RRI across the breadth of the programme ERA4Heatlth will be implemented in 2 phases: . Phase 1 (2 years) will implement joint calls focused on nutrition and lifestyle-related diseases, cardiovascular diseases and nanomedicine (4 in two years). In parallel, it will establish a supporting framework to overcome the challenges in launching international IICSs joint calls. . Phase 2, if the EC approves it: additional multinational calls for IICSs and joint calls for other priority areas will be launched in accordance with the decision of the Health Programme Committee taken at the end of previous Phase 34 partners (20 from EU, 3 Third Countries associated to HE and 2 non-associated, non EU), will commit 90,510,000€, during the 3 first years, as financial support to third parties. |
| Partner countries: |
Austria, Belgium, Denmark, Egypt, France, Germany, Greece, Hungary, Ireland, Israel, Italy, Latvia, Lithuania, Netherlands, Norway, Poland, Portugal, Romania, Spain, Turkey |
| TEAR-Precision - Implementation of Tear Fluid Biomarkers in Precision Medicine |
| Duration: |
21. 10. 2025 - 20. 10. 2029 |
| Evidence number: |
CA24112 |
| Program: |
COST |
| Project leader: |
RNDr. Horváthová Kajabová Viera, PhD. |
| Annotation: |
Tear fluid is a dynamic and multifaceted biological fluid crucial for ocular surface health. Often underestimated, its complexity transcends its lubricating function. Recently, tear fluid has gained widespread attention as an non-invasive source of biomarkers, offering insights into ocular health, but also providing glimpses into systemic and neurological well-being. This emerging field of tear biomarkers holds great promise for diagnostic and therapeutic advancements, potentially reshaping the landscape of precision medicine. Nevertheless, the path from discovery to clinical implementation is marked by significant challenges and complexities.One of the most significant hurdles lies in the variability observed in tear fluid research, attributable to the lack of standardized methodologies for tear fluid collection, storage (biobanking), normalization and reporting. These variations significantly affect the development of tear-based point-of-care tests, causing a delay in the clinical use of tear biomarkers. Fragmentation of tear fluid research groups and institutions exacerbates these challenges. Collaboration between researchers is hindered by this lack of generalized standards and guidelines, as well as the absence of a common platform for knowledge and resource sharing.TEAR-Precision action aims to address these challenges. It will bring together a multidisciplinary and international network of clinicians and researchers in the field. Creating consensus-based protocols and recommendations for best practices will bridge the gap between scientific discovery and clinical implementation. The anticipated knowledge creation and transfer will ensure that Europe can stay at the forefront of tear fluid research and its clinical applications in the field of precision medicine. |
| Project website: |
https://e-services.cost.eu/action/CA24112 |
| SIGMA-1EUROPE - European Network for Sigma-1 Receptor as a Therapeutic Opportunity |
| Duration: |
25. 10. 2024 - 24. 10. 2028 |
| Evidence number: |
CA23156 |
| Program: |
COST |
| Project leader: |
RNDr. Cagalinec Michal, PhD. |
| SAS cosolvers: |
RNDr. Borecká Silvia, PhD., RNDr. Gašperíková Daniela, DrSc., RNDr. Škopková Martina, PhD., RNDr. Zahradníková, ml. Alexandra, PhD. |
| Other cosolvers: |
Institut national de la Sante et de la Recherche Medicale INSER |
| Annotation: |
The sigma-1 receptor (S1R) is a ligand-regulated endoplasmic reticulum chaperone protein and a target for innovative compounds for the treatment of neurodegenerative and inflammatory diseases, cancers and pain diseases. The SIGMA-1 EUROPE network will bring together disciplines and expertises across Europe to advance the exploration and identification of the role of the Sigma-1 receptor in physiology and pathologies, to design innovative S1R ligands for cellular biology and medicine, and ultimately to train young researchers and innovators to revise our views of the diseases, to think out-of-the-box and explore novel and innovativetherapeutic opportunities. |
| Partner countries: |
Austria, Belgium, Estonia, France, Georgia, Germany, Hungary, Israel, Italy |
| TEIDe - Tailored Exercise Interventions for Dementia prEvention: bridging research evidence and primary care practice |
| Duration: |
1. 5. 2025 - 30. 4. 2028 |
| Evidence number: |
ERA4Health/2024/1075.C/TEIDe |
| Program: |
ERANET |
| Project leader: |
prof. MUDr. Ukropcová Barbara, PhD. |
| SAS cosolvers: |
Mgr. Alchus Laiferová Nikoleta, PhD., Mgr. Barkova Daria, Mgr. Dubajová Petra, Mgr. Klepochová Radka, PhD., Mgr. Kurdiová Timea, PhD., PharmDr. Marček Malenovská Karin, PhD., MSc. Motahari Rad Morteza, PhD., Mgr. Nováková Zuzana, PhD., PharmDr. Olešová Dominika, PhD., MVDr. Ondičová Katarína, PhD., Bc. Mgr. Slobodová Lucia, PhD., Mgr. Ukropec Jozef, DrSc. |
| Annotation: |
The TEIDe project aims to identify individuals at high risk of dementia and enhance understanding of the interplay between exercise and cognitive aging. We will establish an integrated framework, combining predictive, precision, mechanistic, and clinical application approaches for the effective prevention of dementia. The four main research questions focus on (i) the discriminative power of dementia risk scores; (ii) optimal types and doses of exercise that confer cognitive benefits based on individual patient characteristics;(iii) the underlying mechanisms of the effect of exercise on cognition; and (iv) the feasibility of implementing a holistic approach in primary healthcare settings.For this, we leverage data from existing cohort studies with over 3 million people and from 7 completed and rigorously conducted exercise-based randomized control trials (RCTs) in middle-aged and older- aged adults with a range of cognitive function. With nine partners from eight countries (i.e., Spain, Norway, Germany, Italy, Slovakia, Romania, USA and Canada), the consortium combines academia, healthcare, enterprise, and operational stakeholders.This Project will generate at least four products which can be implemented in healthcare systems in the relatively short term such as (i) dementia risk scores, (ii) exercise prescription algorithms, (iii) user-friendly exercise manuals, and (iv) modifiable risk factors for non-pharmaceutical treatment. The deliverables will benefit patients and clinicians, contributing to the prevention of cognitive decline and early-stage Alzheimer\'s disease, promoting personalized medicine in dementia care. The TEIDe project stands as a collaborative effort to advance world-class research and strengthen research links, paving the way for improved prediction of treatment benefits and personalized interventions. |
| Partner countries: |
Canada, Germany, Italy, Norway, Romania, Spain, United States |
| A4L_BRIDGE - Alliance4Life Bridging the Research and Innovation Gap in Life Sciences |
| Duration: |
1. 3. 2024 - 29. 2. 2028 |
| Evidence number: |
101136453 |
| Program: |
Horizont Európa |
| Project leader: |
prof. RNDr. Pastoreková Silvia, DrSc. |
| SAS cosolvers: |
Mgr. Bartíková Pavlína, PhD., RNDr. Gašperíková Daniela, DrSc., Mgr. Grman Marián, PhD., Mgr. Jendroľová Lucia, Ing. Karhánek Miloslav, PhD., RNDr. Klempa Boris, DrSc., MVDr. Kopáček Juraj, DrSc., RNDr. Lopušná Katarína, PhD., Mgr. Rybárová Ela, Mgr. Sabo Miroslav, PhD., Mgr. Štibrániová Iveta, PhD., MUDr. Vlček Miroslav, PhD. |
| Annotation: |
The persisting R&I gap between Western and Eastern Europe is a major challenge to the EU. It includes under-developed R&I ecosystems, a lower ability to attract and retain talents, single-track research careers with a lack of modern HR, and fragmented industry-academia collaboration. To improve the situation in Central and Eastern Europe (CEE), Alliance for Life Sciences (Alliance4Life) was formed by 12 progressive health research institutions and universities in 11 CEE countries. Since 2018 it has become a lively community and role model of modern institutional governance and excellent research in CEE, piloted strategic institutional reforms, and succeeded in influencing national R&I reforms and EU policy. With the A4L_BRIDGE project, the alliance focuses on a broader implementation of the successfully piloted strategic changes toward enhanced attractiveness, competitiveness, and innovation strength, and newly also addresses excellence in higher education. The scientific collaboration will be boosted by a Virtual Research Centre, connecting different research groups, and thanks to seed funding, initial research projects with IP originating in CEE will be prepared to be developed into RIA projects for Horizon Europe. The alliance will develop a complex educational matrix, including mentoring, e-learning, and international internships, targeting both academic and non-academic staff in all career stages. The Industry Relationship Platform will stimulate knowledge transfer and partaking in applied research projects. Societal actors will be invited to shape the research agendas and will be addressed at events for end users of health research results. Events, webinars, and dissemination activities will target national stakeholders and policymakers, promoting ERA values and supporting the empowering of low-performing regions in their R&I upscale. The A4L_BRIDGE project will thus significantly contribute to bridging the gap in R&I performance in the EU. |
| Partner countries: |
Bulgaria, Croatia, Czech Republic, Estonia, Hungary, Ireland, Latvia, Lithuania, Poland, Romania, Slovenia |
| Project website: |
https://alliance4life.ceitec.cz |
| ATHEM-03-GEN - Genomic instability in cells from persons exposed to RF from base stations |
| Duration: |
8. 9. 2021 - 31. 12. 2027 |
| Evidence number: |
5916145 |
| Program: |
Iné |
| Project leader: |
doc. Ing. Beliaev Igor, DrSc. |
| SAS cosolvers: |
Mgr. Durdík Matúš, PhD., Gulati Sachin, PhD., Mgr. Jakl Lukáš, PhD., Mgr. Kochanová Dominika, PhD., Mgr. Košík Pavol, PhD., RNDr. Marková Eva, CSc., RNDr. Škorvaga Milan, CSc., Mgr. Vigašová Katarína, PhD. |
| Other cosolvers: |
RA Tilo Rosier, Monika Krout, Tim Krout, Roman Schilling, Dietrich Moldan |
| Annotation: |
The blood samples from persons exposed to radiofrequency radiation (RF) from base stations will be analyzed for DNA damage and genetic instability using comprehensive techniques and endpoints including oxidative damage, comet assay, chromosomal aberrations, micronuclei assay, preleukemic gene fusions. The data will be correlated with RF exposures provided by the German partner. |
| Partner countries: |
Austria, Germany, Slovakia |
| ZOE - Zoonoses Emergence across Degraded and Restored Forest Ecosystems |
| Duration: |
1. 1. 2024 - 31. 12. 2027 |
| Evidence number: |
101135094 |
| Program: |
Horizont Európa |
| Project leader: |
RNDr. Klempa Boris, DrSc. |
| Annotation: |
Ecosystem degradation and biodiversity loss may facilitate the emergence of zoonotic diseases. The 4-year ZOE project will analyze the links between landcover and land use changes in tropical biodiversity hot-spots facing loss of primary forest and biodiversity and in temperate regions that have undergone ecosystem degradation and deforestation over historical timescales. In areas experiencing different levels of ecosystem degradation, biodiversity assessments will be based on remote sensing-based GIS analysis of landscape structures, geobotanic plant mapping, and targeted trapping of rodents, ticks, and mosquitoes, as prototypic reservoirs and vectors of zoonotic diseases (macro-organism scale). Host and soil-associated microbiome and virome high-throughput sequencing will be combined with assessment of human exposure to prototypic zoonotic pathogens, using high-throughput serological analyses (microbiological scale). ZOE will link with local communities and stakeholders to address perceived land use and land cover changes, disease occurrence, coping strategies, and risk behaviour. Results will be synthesized in modelling and risk mapping frameworks linking biodiversity loss and zoonotic disease risks and tested in forecasting scenarios to feed into cost-efficient monitoring schemes and early warning systems. An online knowledge platform will be created to link all relevant stakeholders of the biodiversity-health nexus, including other EU-funded consortia, national and supranational organizations stakeholders, local communities, and the public. A joint stakeholder conference will be organized, and community engagement workshops will specifically co-create and advance knowledge in local communities involved in ZOE. The ZOE project is proposed by an interdisciplinary consortium with expertise in geography, geobotanics, ecology, virology, immunology, epidemiology, sociology, psychology, anthropology and science dissemination from 7 EU and 4 American countries. |
| Partner countries: |
Austria, Costa Rica, France, Germany, Guatemala, Mexico, Netherlands, Slovenia, Spain, United States |
| Project website: |
https://www.zoe-project.eu/ |
| WIMANET - Wildlife Malaria Network |
| Duration: |
28. 9. 2023 - 27. 9. 2027 |
| Evidence number: |
CA22108 |
| Program: |
COST |
| Project leader: |
RNDr. Minichová Lenka, PhD. |
| Annotation: |
Vector-borne diseases, and emerging infectious diseases of wildlife, are major contributors to the global disease burden and of increasing concern globally. Haemosporidian parasites are ubiquitous in nature, hugely diverse, and associated with morbidity and mortality across taxa, including humans, livestock and wildlife. Many research groups globally focus on these parasites as model systems for addressing a broad range of ecological and evolutionary questions with economic and health implications. This Action will bring together individuals and research groups to focus on coordinating research objectives to which multiple groups can contribute existing datasets, meaning that questions can be addressed at a global, rather than a local or regional, scale. Ornithologists, mammologists and herpetologists have a long history of investigating haemosporidian parasites in natural populations; these studies have provided insights into host-parasite associations, parasite geographic distributions, host-switching and the context-dependence of host-parasite relationships, alongside pathogenic impacts and conservation implications of haemosporidian infections. Increasingly, research groups are investigating the vectors of these parasites, and utilising novel genetic techniques to understand parasite gene expression, among many other examples. Coordinating and sharing research efforts between groups offers huge potential for large-scale collaborative research initiatives. This Action will promote the development of a common research agenda by providing opportunities for training, collaboration and knowledge exchange, targeting diverse researchers across disciplines to foster an interdisciplinary approach, whilst also recruiting and supporting a diversity of new researchers. The Action will target stakeholders, policymakers and the general public to endorse knowledge transfer and maximise the reach of the network. |
| Project website: |
https://www.cost.eu/actions/CA22108/#tabs+Name:Description |
| REACH - Reversing Epitranscriptomic Alterations for CHemosensitization of Pancreatic Cancer |
| Duration: |
1. 9. 2024 - 31. 8. 2027 |
| Evidence number: |
TRANSCAN-3/2023/977.C/REACH |
| Program: |
ERANET |
| Project leader: |
Mgr. Smolková Božena, PhD. |
| SAS cosolvers: |
Mgr. Buociková Verona, PhD., Ing. Buríková Monika, PhD., MUDr. Dubovan Peter, RNDr. Horváthová Kajabová Viera, PhD., prof. MUDr. Mego Michal, DrSc., RNDr. Pacalajová Mária, PhD., doc. Mgr. Šoltýsová Andrea, PhD., MUDr. Tomáš Miroslav, PhD. |
| Partner countries: |
Germany, Latvia, Spain |
| ADDIT-CE - Alzheimer\'s Disease Diagnostics Innovation and Translation to Clinical Practice in Central Europe |
| Duration: |
1. 1. 2023 - 31. 12. 2026 |
| Evidence number: |
101087124 |
| Program: |
Horizont Európa |
| Project leader: |
prof. MUDr. Ukropcová Barbara, PhD. |
| SAS cosolvers: |
Mgr. Kurdiová Timea, PhD., Mgr. Ukropec Jozef, DrSc., doc. MVDr. Žilka Norbert, DrSc. |
| Other cosolvers: |
Centrum Memory |
| Annotation: |
Alzheimer’s disease (AD) affects millions of individuals worldwide, and currently there are no effective disease-modifying therapies. Prompt AD diagnosis is beneficial with respect to care and delay of disease progression. However, the implementation of modern AD diagnostics in clinical practice in Czechia and Slovakia is fragmented. To address this, the EU-funded ADDIT-CE project will support the cooperation between academia, business, government and civil society. The partnership is expected to strengthen research and innovation in the field of AD diagnostics and introduce novel technologies into AD clinical management. ADDIT-CE will help design a national plan for combatting dementia and establish a functional innovation ecosystem that will revolutionise diagnostic approaches and continue to serve society even after the project’s completion. |
| Partner countries: |
Czech Republic |
| Project website: |
https://cordis.europa.eu/project/id/101087124 |
| RESIST-D - Reward-stress interactions as neurobiological substrate for resilience and vulnerability in mental health and depression: A translational large-scale project |
| Duration: |
1. 1. 2024 - 31. 12. 2026 |
| Evidence number: |
NEURON_RV-114 |
| Program: |
ERANET |
| Project leader: |
RNDr. Hlaváčová Nataša, PhD. |
| SAS cosolvers: |
RNDr. Graban Ján, PhD., prof. PharmDr. Ježová Daniela, DrSc., RNDr. Karailiev Peter, PhD., RNDr. Karailievová Lucia, PhD., Mgr. Nagyová Anabela, RNDr. Puhová Agneša, PhD., Mgr. Reinerová Mária, PharmDr. Romanová Zuzana, PhD., MUDr. Vančová Annamária |
| Partner countries: |
France, Germany, Ireland, Romania |
| Preclinical studies on the importance of brain-gut interaction in the development of stress-related disorders. |
| Duration: |
1. 1. 2025 - 31. 12. 2026 |
| Evidence number: |
HAS-SAS-2024-4 |
| Program: |
Mobility |
| Project leader: |
prof. PharmDr. Ježová Daniela, DrSc. |
| SAS cosolvers: |
RNDr. Hlaváčová Nataša, PhD., Mgr. Hodúrová Zuzana, PhD., RNDr. Karailiev Peter, PhD., RNDr. Karailievová Lucia, PhD., Mgr. Nagyová Anabela, MSc. Nejati Bervanlou Reyhaneh, Mgr. Reinerová Mária, MUDr. Vančová Annamária |
| Partner countries: |
Hungary |
| Siponimod\'s role in acute phase of spinal cord injury |
| Duration: |
1. 1. 2025 - 31. 12. 2026 |
| Evidence number: |
PAS-SAS-2024-12 |
| Program: |
Mobility |
| Project leader: |
RNDr. Kisucká Alexandra, PhD. |
| SAS cosolvers: |
RNDr. Ileninová Mária, PhD., RNDr. Kiss Bimbová Katarína, PhD., RNDr. Kuruc Tomáš, PhD., RNDr. Lukáčová Nadežda, DrSc. |
| Annotation: |
This project is designed to reflect the needs of clinicians and ensure that research and discoveries directly benefit clinical practice. Our previous joint research revealed several changes in genes encoding sphingosine 1-phosphate (S1P) receptors (S1PRs), sphingosine kinase, and sirtuin 1 (SIRT1) in the spinal cord and cerebellum after Th9 spinal cord compression. Additionally, a promising protective effect of Siponimod (S1PR1 and -5 modulator) was observed. Therefore, we decided to explore further the impact of Siponimod, administered in a manner that mirrors hospital protocols, on reducing inflammation and hypoxia, and its influence on sphingosine-1-phosphate (S1P) receptors and SIRT1 expression during the acute phase of spinal cord injury. |
| Partner countries: |
Poland |
| IMMUNO-model - Modelling immunotherapy response and toxicity in cancer |
| Duration: |
2. 11. 2022 - 1. 11. 2026 |
| Evidence number: |
CA21135 |
| Program: |
COST |
| Project leader: |
Mgr. Smolková Božena, PhD. |
| Other cosolvers: |
1. Medical Unive |
| Annotation: |
The IMMUNO-model COST Action aims to foster research and innovation in the field of preclinical immuno-oncology models with the ultimate goal of advancing in the treatment of cancer patients by improving their outcomes and quality of life. The unprecedented change that immunotherapy has represented in the treatment of cancer is best illustrated by the spectacular results obtained in previously incurable malignancies, such as metastatic melanoma. However, the widespread use of these therapies has been hindered by their limited effectiveness and associated toxicities. A better understanding on the complex interactions between tumor cells and the immune system is strictly required to address these problems, and to develop more effective and safer immunotherapies. However, one of the most important obstacles in immuno-oncology research is the scarcity of preclinical models that faithfully recapitulate human immunity and contribute to identify novel therapeutic targets, characterize biomarkers of therapeutic response and toxicity, and generate reliable data on drug synergies. IMMUNO-model will bring together European researchers from diverse sectors (academia, clinical, industry) with the common goal of establishing a Network that endorses immuno-oncology research by specifically promoting the sharing, standardization and application of immunotherapy preclinical models. |
| Project website: |
https://www.cost.eu/actions/CA21135/ |
| PRAGMATICK - Prevention, anticipation and mitigation of tick-borne disease risk applying the DAMA protocol |
| Duration: |
18. 10. 2022 - 17. 10. 2026 |
| Evidence number: |
CA 21170 |
| Program: |
COST |
| Project leader: |
Mgr. Špitalská Eva, DrSc. |
| Annotation: |
Emerging infectious diseases (EIDs) represent a national security threat for every country, exacerbated by climate change, human population expansion, urbanization, and globalization. Based on theoretical expectations previously EIDs were thought to be rare and impossible to anticipate because they require novel genetic mutations to infect novel hosts. A new conceptual framework has been developing for nearly 40 years and has recently been articulated in a manner that leads directly to a protocol for taking proactive or anticipatory steps in coping with EIDs, especially those numerous high probability/low impact pathogens. The framework is called the Stockholm paradigm, which shows that a major trigger of emerging disease, now and in the past, has been climate change. The PRAGMATICK COST action aims to disseminate knowledge and promote the application of the Stockholm paradigm in order to anticipate and mitigate disease risk associated with the presence and spread of ticks and tick-borne pathogens (TBPs) under anthropogenic pressure and changing climate. This research network will apply the comprehensive and highly focused DAMA (Document, Assess, Monitor, Act) protocol that allows to “anticipate to mitigate” emerging diseases. The main focus is on urban tick and TBP hotspots and the spread and establishment of ticks and TBPs. PRAGMATICK will find new ticks and tick-borne pathogens before they find us. By applying citizen science and supporting capacity building in the domain of tick and tick-borne disease prevention, the Action will eventually lead to new and improved insights in the potential threats related to this important group of vectors across Europe. |
| PRAGMATICK - Prevention, anticipation and mitigation of tick-borne disease risk applying the DAMA protocol |
| Duration: |
18. 10. 2022 - 17. 10. 2026 |
| Evidence number: |
CA21170 |
| Program: |
COST |
| Project leader: |
RNDr. Minichová Lenka, PhD. |
| SAS cosolvers: |
Mgr. Špitalská Eva, DrSc. |
| Annotation: |
Emerging infectious diseases (EIDs) represent a national security threat for every country, exacerbated by climate change, human population expansion, urbanization, and globalization. Based on theoretical expectations previously EIDs were thought to be rare and impossible to anticipate because they require novel genetic mutations to infect novel hosts. A new conceptual framework has been developing for nearly 40 years and has recently been articulated in a manner that leads directly to a protocol for taking proactive or anticipatory steps in coping with EIDs, especially those numerous high probability/low impact pathogens. The framework is called the Stockholm paradigm, which shows that a major trigger of emerging disease, now and in the past, has been climate change. The PRAGMATICK COST action aims to disseminate knowledge and promote the application of the Stockholm paradigm in order to anticipate and mitigate disease risk associated with the presence and spread of ticks and tick-borne pathogens (TBPs) under anthropogenic pressure and changing climate. This research network will apply the comprehensive and highly focused DAMA (Document, Assess, Monitor, Act) protocol that allows to “anticipate to mitigate” emerging diseases. The main focus is on urban tick and TBP hotspots and the spread and establishment of ticks and TBPs. PRAGMATICK will find new ticks and tick-borne pathogens before they find us. By applying citizen science and supporting capacity building in the domain of tick and tick-borne disease prevention, the Action will eventually lead to new and improved insights in the potential threats related to this important group of vectors across Europe. |
| Project website: |
https://www.cost.eu/actions/CA21170/#tabs+Name:Description |
| TRANSPAN - Identification of biological markers for prevention and translational medicine in pancreatic cancer |
| Duration: |
11. 10. 2022 - 10. 10. 2026 |
| Evidence number: |
CA21116 |
| Program: |
COST |
| Project leader: |
Mgr. Smolková Božena, PhD. |
| Other cosolvers: |
1. Un |
| Annotation: |
Pancreatic cancer (PC) has a high mortality rate and is projected to become a massive public health problem in Europe. This Action will boost research on prevention of PC, particularly in the discovery of genetic risk factors, risk stratification, identification of biomarkers for early detection and patient monitoring, elucidation of biological mechanisms and functional pharmacogenomics for personalized medicine. These aims will be attained by expanding an existing interdisciplinary network.The Action will be organized in the following working groups:• Disease risk profiling. This WG will use germline genetic variants, epigenetics, transcriptomics and environmental factors to model disease risk and apply risk stratification scores to better select individuals eligible to be screened for PC or its precursors.• Non-invasive biomarkers. This WG will apply state-of-the-art liquid biopsies for the detection and characterization of circulating tumor cells and DNA, tumor-derived exosomes, tumor-educated platelets, epigenetic markers, and will test their diagnostic value for PC precursors and early-stage PC.• Tumor profiling. Genomic, epigenomic and transcriptional profiling of PC and its precursors in a multiregional analysis fashion will be used to identify novel biomarkers with prognosis and predictive value for PC patient stratification.• Functional genomics and therapy. This WG will functionally validate candidate genetic variants from germline or tumor studies by using cutting-edge approaches such as CRISPR-Cas9 gene editing. It will also generate novel approaches such as organoids / zebrafish avatars to implement (chemo)therapeutic strategies based on the patient in an effort to implement personalized medicine for PC. |
| Partner countries: |
Slovakia |
| Project website: |
https://www.cost.eu/actions/CA21116/ |
| DYNALIFE - Information, Coding, and Biological Function: the Dynamics of Life |
| Duration: |
2. 10. 2023 - 18. 9. 2026 |
| Evidence number: |
CA21169 |
| Program: |
COST |
| Project leader: |
RNDr. Farkaš Robert, CSc. |
| SAS cosolvers: |
Bardačová Magdaléna, Mgr. Beňo Milan, PhD., Mgr. Beňová Liszeková Denisa, PhD. |
| Annotation: |
The previous and current work of our group focuses on the mechanistic aspects of apocrine secretion (AS), a novel and previously incorrectly described type of non-canonical and non-vesicular transport and secretory mechanism. We discovered AS by serendipity in salivary glands of Drosophila, a well defined genetic model organism. Our long-term goal is to decipher molecular and genetic aspects of AS using tools so uniquely available in the fruitfly. As we already found, AS is phylogenetically conserved, and it is present in all eukaryotic metazoans, including human. In addition, AS is implicated also in at least two dozen of human disorders. Material released by AS is considerably enriched in proteins (proteomics identified >1500 entities), and this liquid “soup” contains highly viable or zymogen-like dormant proteins capable of immediate activation upon challenge. All these aspects make phenomenon of apocrine secretion very dynamic biological system. Currently, we are the only research group in the world that deals with elementary molecular-genetic and structural aspects of apocrine secretion per se. |
| Genome Editing to Treat Humans Diseases |
| Duration: |
15. 9. 2022 - 14. 9. 2026 |
| Evidence number: |
CA21113 |
| Program: |
COST |
| Project leader: |
prof. PharmDr. Ježová Daniela, DrSc. |
| SAS cosolvers: |
MMedSc. Dremencov Eliyahu, DrSc., RNDr. Graban Ján, PhD., RNDr. Hlaváčová Nataša, PhD., PharmDr. Hrivíková Katarína, PhD., MUDr. Kapsdorfer Daniela, PhD., RNDr. Karailiev Peter, PhD., RNDr. Karailievová Lucia, PhD., Mgr. Oravcová Henrieta, PhD., RNDr. Puhová Agneša, PhD., PharmDr. Romanová Zuzana, PhD. |
| Partner countries: |
Cyprus, Denmark, Germany, Italy, Luxembourg, Malta, Norway, Poland |
